Eli Lilly (LLY)
(Delayed Data from NYSE)
$952.74 USD
-1.43 (-0.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$952.74 USD
-1.43 (-0.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
by Zacks Equity Research
Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More
by Arpita Dutt
This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.
Endocyte (ECYT) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated report on Endocyte, Inc. (ECYT) on May 17.
5 Reasons Why Merck (MRK) is a Good Stock to Buy Now
by Zacks Equity Research
It looks like a great stock to buy now.
Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.
Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint
by Zacks Equity Research
Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies
The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One
by Zacks Equity Research
The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One
Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit
by Arpita Dutt
Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.
Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved
by Zacks Equity Research
Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.
Merck (MRK) Beats on Q1 Earnings & Sales, Ups Annual View
by Zacks Equity Research
Merck & Co., Inc. (MRK) reported first-quarter 2017 earnings of 88 cents per share, which beat the Zacks Consensus Estimate of 83 cents.
Drug Stocks Q1 Earnings Slated for May 2: MRK, PFE & GILD
by Zacks Equity Research
The Q1 earnings season is in full swing with financial results from 288 S&P 500 members or 63.8% of the index already out as of Apr 28, 2017.
Company News for April 26, 2017
by Zacks Equity Research
Companies in the News are: RAD,GLW,LLY,NFLX
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
by Zacks Equity Research
Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Key Factors to Look Out for in Celgene's (CELG) Q1 Results
by Arpita Dutt
Apart from the usual earnings and revenue numbers, investors will be focused on the performance of Celgene's (CELG) key products and its pipeline progress.
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
by Zacks Equity Research
Eli Lilly (LLY) Tops Earnings in Q1; Sales Miss Slightly
What's in Store for Vertex (VRTX) this Earnings Season?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc. (VRTX) is scheduled to report first-quarter 2017 results on Apr 27, after the market closes.
3 Key Factors to Look Out for in Biogen's Q1 Results
by Arpita Dutt
With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
Why Eli Lilly (LLY) Might Surprise This Earnings Season
by Zacks Equity Research
Eli Lilly (LLY) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
S&P Global (SPGI) to Post Q1 Earnings: A Beat in the Cards?
by Zacks Equity Research
S&P Global, Inc. (SPGI) is slated to report first-quarter 2017 results on Apr 25, before the markets open.
TransUnion (TRU) Q1 Earnings: What's in Store this Time?
by Zacks Equity Research
TransUnion (TRU) is scheduled to release first-quarter 2017 results before the market opens on Apr 25.
Eli Lilly (LLY) Up 8.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Eli Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS
by Zacks Equity Research
As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years.
CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up
by Zacks Equity Research
CytRx Corporation (CYTR) announced that the it has reached an agreement with the regarding the path to filing for its new drug application (NDA) for its lead candidate aldoxorubicin being developed for the treatment of soft tissue sarcomas (STS).
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.
Company News for April 18, 2017
by Zacks Equity Research
Companies in the News are: MGI,LLY,ASH,ALR,ABT